F. Douguet, La faiblesse des négociations du soin entre professionnels et avec les proches de patients hospitalisés à la suite d?un AVC grave, Les négociations du soin, pp.235-246, 2014.

E. Touzé and D. Ciocanu, Survenue d?un accident ischémique cérébral chez un patient en fibrillation atriale sous anticoagulant oral : que faire de plus ?, La Presse Médicale, vol.43, issue.7-8, pp.784-788, 2014.

, Annexe 2. Problèmes concernant les données analysées à la section 4.6, 2007.

J. D'après-kepplinger, A. Prakapenia, K. Barlinn, G. Siegert, S. Gehrisch et al., Standardized use of novel oral anticoagulants plasma level thresholds in a new thrombolysis decision making protocol, J Thromb Thrombolysis. févr, vol.41, issue.2, pp.293-300, 2016.

J. I. Weitz and J. Harenberg, New developments in anticoagulants: Past, present and future, Thrombosis and Haemostasis, vol.117, issue.07, pp.1283-1288, 2017.

J. I. Weitz and J. Harenberg, New developments in anticoagulants: Past, present and future, Thrombosis and Haemostasis, vol.117, issue.07, pp.1283-1288, 2017.

R. Shah, K. C. Rogers, K. Matin, R. Askari, and S. V. Rao, An updated comprehensive meta-analysis of bivalirudin vs heparin use in primary percutaneous coronary intervention, American Heart Journal, vol.171, issue.1, pp.14-24, 2016.

A. Lambert, Les anticoagulants oraux directs (AODs) chez le sujet âgé : données de pharmacovigilance sur le territoire national, Les cahiers de l'année gérontologique, vol.7, issue.3, pp.98-102, 2015.

J. Stangier and A. Clemens, Pharmacology, Pharmacokinetics, and Pharmacodynamics of Dabigatran Etexilate, an Oral Direct Thrombin Inhibitor, Clinical and Applied Thrombosis/Hemostasis, vol.15, issue.1_suppl, pp.9S-16S, 2009.

J. Travis, Answer: covfefe? Play <cite>Science</cite>?s election 2020 crossword puzzle!, Science, 2020.

N. H. Disponible-sur-;-hauel, H. Nar, H. Priepke, U. Ries, J. Stassen et al., Structure-based design of novel potent nonpeptide thrombin inhibitors, J Med Chem. 25 avr, vol.45, issue.9, pp.1757-66, 2002.

J. Van-ryn, N. Hauel, L. Waldmann, and W. Wienen, Dabigatran Inhibits Both Clot-Bound and Fluid Phase Thrombin In Vitro: Effects Compared to Heparin and Hirudin., Blood, vol.110, issue.11, pp.3998-3998, 2007.

S. Blech, T. Ebner, E. Ludwig-schwellinger, J. Stangier, and W. Roth, The Metabolism and Disposition of the Oral Direct Thrombin Inhibitor, Dabigatran, in Humans, Drug Metabolism and Disposition, vol.36, issue.2, pp.386-399, 2007.

W. G. Eisert, N. Hauel, J. Stangier, W. Wienen, A. Clemens et al., Dabigatran: An Oral Novel Potent Reversible Nonpeptide Inhibitor of Thrombin, Arteriosclerosis, Thrombosis, and Vascular Biology, vol.30, issue.10, pp.1885-1889, 2010.

J. Stangier, H. Stähle, K. Rathgen, and R. Fuhr, Pharmacokinetics and Pharmacodynamics of the Direct Oral Thrombin Inhibitor Dabigatran in Healthy Elderly Subjects, Clinical Pharmacokinetics, vol.47, issue.1, pp.47-59, 2008.

J. Stangier, K. Rathgen, H. Stähle, and D. Mazur, Influence of Renal Impairment on the Pharmacokinetics and Pharmacodynamics of Oral Dabigatran Etexilate, Clinical Pharmacokinetics, vol.49, issue.4, pp.259-268, 2010.

J. Stangier, H. Stähle, K. Rathgen, W. Roth, and K. Shakeri-nejad, Pharmacokinetics and Pharmacodynamics of Dabigatran Etexilate, an Oral Direct Thrombin Inhibitor, Are Not Affected by Moderate Hepatic Impairment, The Journal of Clinical Pharmacology, vol.48, issue.12, pp.1411-1419, 2008.

F. Disponible-sur-;-schiele, J. Van-ryn, K. Canada, C. Newsome, E. Sepulveda et al., A specific antidote for dabigatran: functional and structural characterization, Blood. 2 mai, vol.121, issue.18, pp.3554-62, 2013.

S. Glund, V. Moschetti, S. Norris, J. Stangier, M. Schmohl et al., A randomised study in healthy volunteers to investigate the safety, tolerability and pharmacokinetics of idarucizumab, a specific antidote to dabigatran, Thromb Haemost. mai, vol.113, issue.5, pp.943-51, 2015.

C. V. Pollack, P. A. Reilly, J. Eikelboom, S. Glund, P. Verhamme et al., Idarucizumab for Dabigatran Reversal, New England Journal of Medicine, vol.373, issue.6, pp.511-520, 2015.

C. V. Pollack, P. A. Reilly, J. Van-ryn, J. W. Eikelboom, S. Glund et al.,

, Dabigatran Reversal with Idarucizumab, New England Journal of Medicine, vol.377, issue.17, pp.1690-1692, 2017.

X. Jiang, E. J. Crain, J. M. Luettgen, W. A. Schumacher, and P. C. Wong, Apixaban, an oral direct factor Xa inhibitor, inhibits human clot-bound factor Xa activity in vitro, Thrombosis and Haemostasis, vol.101, issue.04, pp.780-782, 2009.

E. Perzborn, J. Strassburger, A. Wilmen, J. Pohlmann, S. Roehrig et al., In vitro and in vivo studies of the novel antithrombotic agent BAY 59-7939-an oral, direct Factor Xa inhibitor, Journal of Thrombosis and Haemostasis, vol.3, issue.3, pp.514-521, 2005.

L. Anticoagulants-en-france-en, Les anticoagulants en France en 2012 : Etat des lieux et surveillance. Juillet 2012, Sang thrombose vaisseaux, vol.24, issue.9, pp.416-439, 2012.

D. Sur, FEVR, vol.14

D. Sur,

P. Maison, C. Picot, M. A. Courné, L. De-haro, and F. Cardona, Veille et sécurité sanitaire des toxiques ? implication des agences sanitaires ? Agence nationale de sécurité du médicament et des produits de santé (ANSM), Toxicologie Analytique et Clinique, vol.27, issue.2, pp.124-125, 2015.

S. Roehrig, A. Straub, J. Pohlmann, T. Lampe, J. Pernerstorfer et al., Discovery of the Novel Antithrombotic Agent 5-Chloro-N-({(5S)-2-oxo-3- [4-(3-oxomorpholin-4-yl)phenyl]-1,3-oxazolidin-5-yl}methyl)thiophene- 2-carboxamide (BAY 59-7939): An Oral, Direct Factor Xa Inhibitor, Journal of Medicinal Chemistry, vol.48, issue.19, pp.5900-5908, 2005.

D. Sur, pellic vertisol, Dictionary Geotechnical Engineering/Wörterbuch GeoTechnik, pp.972-972, 2014.

D. Sur, pellic vertisol, Dictionary Geotechnical Engineering/Wörterbuch GeoTechnik, pp.972-972, 2014.

J. Disponible-sur-;-stampfuss, D. Kubitza, M. Becka, and W. Mueck, The effect of food on the absorption and pharmacokinetics of rivaroxaban, Int J Clin Pharmacol Ther. juill, vol.51, issue.7, pp.549-61, 2013.

D. Kubitza, M. Becka, B. Voith, M. Zuehlsdorf, and G. Wensing, Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct factor Xa inhibitor, Clinical Pharmacology & Therapeutics, vol.78, issue.4, pp.412-421, 2005.

D. Kubitza, M. Becka, G. Wensing, B. Voith, and M. Zuehlsdorf, Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939?an oral, direct Factor Xa inhibitor?after multiple dosing in healthy male subjects, European Journal of Clinical Pharmacology, vol.61, issue.12, pp.873-880, 2005.

C. Weinz, U. Buetehorn, H. Daehler, C. Kohlsdorfer, U. Pleiss et al., Pharmacokinetics of BAY 59-7939 ? an oral, direct Factor Xa inhibitor ? in rats and dogs, Xenobiotica, vol.35, issue.9, pp.891-910, 2005.

W. Mueck, M. Becka, D. Kubitza, B. Voith, and M. Zuehlsdorf, Population model of the pharmacokinetics and pharmacodynamics of rivaroxaban – an oral, direct Factor Xa inhibitor – in healthy subjects, Int. Journal of Clinical Pharmacology and Therapeutics, vol.45, issue.06, pp.335-344, 2007.

D. Lang, C. Freudenberger, and C. Weinz, In Vitro Metabolism of Rivaroxaban, an Oral, Direct Factor Xa Inhibitor, in Liver Microsomes and Hepatocytes of Rats, Dogs, and Humans, Drug Metabolism and Disposition, vol.37, issue.5, pp.1046-1055, 2009.

M. J. Gnoth, U. Buetehorn, U. Muenster, T. Schwarz, and S. Sandmann, In Vitro and In Vivo P-Glycoprotein Transport Characteristics of Rivaroxaban, Journal of Pharmacology and Experimental Therapeutics, vol.338, issue.1, pp.372-380, 2011.

S. Hodin, T. Basset, E. Jacqueroux, O. Delezay, A. Clotagatide et al., In Vitro Comparison of the Role of P-Glycoprotein and Breast Cancer Resistance Protein on Direct Oral Anticoagulants Disposition, European Journal of Drug Metabolism and Pharmacokinetics, vol.43, issue.2, pp.183-191, 2017.

W. Mueck, D. Kubitza, and M. Becka, Co-administration of rivaroxaban with drugs that share its elimination pathways: pharmacokinetic effects in healthy subjects, British Journal of Clinical Pharmacology, vol.76, issue.3, pp.455-466, 2013.

C. Weinz, T. Schwarz, D. Kubitza, W. Mueck, and D. Lang, Metabolism and Excretion of Rivaroxaban, an Oral, Direct Factor Xa Inhibitor, in Rats, Dogs, and Humans, Drug Metabolism and Disposition, vol.37, issue.5, pp.1056-1064, 2009.

D. Kubitza, M. Becka, A. Roth, and W. Mueck, The Influence of Age and Gender on the Pharmacokinetics and Pharmacodynamics of Rivaroxaban-An Oral, Direct Factor Xa Inhibitor, The Journal of Clinical Pharmacology, vol.53, issue.3, pp.249-255, 2013.

D. Kubitza, M. Becka, W. Mueck, A. Halabi, H. Maatouk et al., Effects of renal impairment on the pharmacokinetics, pharmacodynamics and safety of rivaroxaban, an oral, direct Factor Xa inhibitor, British Journal of Clinical Pharmacology, vol.70, issue.5, pp.703-712, 2010.

D. Kubitza, A. Roth, M. Becka, A. Alatrach, A. Halabi et al., Effect of hepatic impairment on the pharmacokinetics and pharmacodynamics of a single dose of rivaroxaban, an oral, direct Factor Xa inhibitor, British Journal of Clinical Pharmacology, vol.76, issue.1, pp.89-98, 2013.

W. Byon, S. Garonzik, R. A. Boyd, and C. E. Frost, Apixaban: A Clinical Pharmacokinetic and Pharmacodynamic Review, Clinical Pharmacokinetics, vol.58, issue.10, pp.1265-1279, 2019.

B. Disponible-sur-;-vakkalagadda, C. Frost, W. Byon, R. A. Boyd, J. Wang et al., Effect of Rifampin on the Pharmacokinetics of Apixaban, an Oral Direct Inhibitor of Factor Xa, Am J Cardiovasc Drugs Drugs Devices Interv. avr, vol.16, issue.2, pp.119-146, 2016.

N. Raghavan, C. E. Frost, Z. Yu, K. He, H. Zhang et al., Apixaban Metabolism and Pharmacokinetics after Oral Administration to Humans, Drug Metabolism and Disposition, vol.37, issue.1, pp.74-81, 2008.

C. Frost, J. Wang, S. Nepal, A. Schuster, Y. C. Barrett et al., Apixaban, an oral, direct factor X a inhibitor: single dose safety, pharmacokinetics, pharmacodynamics and food effect in healthy subjects, British Journal of Clinical Pharmacology, vol.75, issue.2, pp.476-487, 2013.

. Apixaban, direct factor Xa inhibitor: single dose safety, pharmacokinetics, pharmacodynamics and food effect in healthy subjects, Br J Clin Pharmacol. févr, vol.75, issue.2, pp.476-87, 2013.

C. Frost, S. Nepal, J. Wang, A. Schuster, W. Byon et al., Safety, pharmacokinetics and pharmacodynamics of multiple oral doses of apixaban, a factor X a inhibitor, in healthy subjects, British Journal of Clinical Pharmacology, vol.76, issue.5, pp.776-786, 2013.

K. He, J. M. Luettgen, D. Zhang, B. He, J. E. Grace et al., Preclinical pharmacokinetics and pharmacodynamics of apixaban, a potent and selective factor Xa inhibitor, European Journal of Drug Metabolism and Pharmacokinetics, vol.36, issue.3, pp.129-139, 2011.

D. Zhang, K. He, J. J. Herbst, J. Kolb, W. Shou et al., Characterization of Efflux Transporters Involved in Distribution and Disposition of Apixaban, Drug Metabolism and Disposition, vol.41, issue.4, pp.827-835, 2013.

L. Wang, D. Zhang, N. Raghavan, M. Yao, L. Ma et al., Correction to ?In Vitro Assessment of Metabolic Drug-Drug Interaction Potential of Apixaban through Cytochrome P450 Phenotyping, Inhibition, and Induction Studies?, Drug Metabolism and Disposition, vol.38, issue.5, pp.887-887, 2010.

C. E. Frost, W. Byon, Y. Song, J. Wang, A. E. Schuster et al., Effect of ketoconazole and diltiazem on the pharmacokinetics of apixaban, an oral direct factor Xa inhibitor, British Journal of Clinical Pharmacology, vol.79, issue.5, pp.838-846, 2015.

M. Chang, Z. Yu, A. Shenker, J. Wang, J. Pursley et al., Effect of renal impairment on the pharmacokinetics, pharmacodynamics, and safety of apixaban, The Journal of Clinical Pharmacology, vol.56, issue.5, pp.637-645, 2015.

X. Wang, G. Tirucherai, T. C. Marbury, J. Wang, M. Chang et al., Pharmacokinetics, pharmacodynamics, and safety of apixaban in subjects with end-stage renal disease on hemodialysis, The Journal of Clinical Pharmacology, vol.56, issue.5, pp.628-636, 2015.

X. Wang, G. Tirucherai, T. C. Marbury, J. Wang, M. Chang et al., Pharmacokinetics, pharmacodynamics, and safety of apixaban in subjects with end-stage renal disease on hemodialysis, The Journal of Clinical Pharmacology, vol.56, issue.5, pp.628-636, 2015.

C. Frost, Y. Cui, Y. Song, J. Wang, Z. Yu et al., Single- and multiple-dose pharmacokinetics, pharmacodynamics, and safety of apixaban in healthy Chinese subjects [Corrigendum], Clinical Pharmacology: Advances and Applications, p.61, 2014.

G. Lu, F. R. Deguzman, S. J. Hollenbach, M. J. Karbarz, K. Abe et al., A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa, Nature Medicine, vol.19, issue.4, pp.446-451, 2013.

D. Siegal, G. Lu, J. M. Leeds, M. Karbarz, J. Castillo et al., Safety, pharmacokinetics, and reversal of apixaban anticoagulation with andexanet alfa, Blood Advances, vol.1, issue.21, pp.1827-1838, 2017.

D. M. Siegal, J. T. Curnutte, S. J. Connolly, G. Lu, P. B. Conley et al., Andexanet Alfa for the Reversal of Factor Xa Inhibitor Activity, New England Journal of Medicine, vol.373, issue.25, pp.2413-2424, 2015.

S. J. Connolly, M. Crowther, J. W. Eikelboom, C. M. Gibson, J. T. Curnutte et al., Full Study Report of Andexanet Alfa for Bleeding Associated with Factor Xa Inhibitors, New England Journal of Medicine, vol.380, issue.14, pp.1326-1335, 2019.

Y. Heo, Andexanet Alfa: First Global Approval, Drugs, vol.78, issue.10, pp.1049-1055, 2018.

. Buckingham-l and . Ondexxya, Summary of opinion: Ondexxya,andexanet alfa, Case Medical Research, 2019.

A. European-medicines, Milling TJ, Kaatz S. Preclinical and Clinical Data for Factor Xa and « Universal » Reversal Agents, Am J Med. nov, vol.129, issue.11S, 2016.

T. Baglin, A. Hillarp, A. Tripodi, I. Elalamy, H. Buller et al., Measuring oral direct inhibitors of thrombin and factor Xa: a recommendation from the Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis, Journal of Thrombosis and Haemostasis, vol.11, issue.4, pp.756-760, 2013.

A. Tripodi, The laboratory and the direct oral anticoagulants, Blood, vol.121, issue.20, pp.4032-4035, 2013.

A. Tamigniau, J. Douxfils, J. Nicolas, B. Devalet, A. Larock et al.,

A. De-torrenté, Rechutes de malaria à Plasmodium vivax: traitement court?, Forum Médical Suisse ? Swiss Medical Forum, vol.14, issue.33, pp.326-359, 2014.

B. H. Simpson, D. M. Reith, N. J. Medlicott, and A. J. Smith, Exposure Response Supports Therapeutic Drug Monitoring for Dabigatran Etexilate in Patients with Atrial Fibrillation, TH Open, vol.03, issue.03, pp.e210-e215, 2019.

P. A. Reilly, T. Lehr, S. Haertter, S. J. Connolly, S. Yusuf et al., The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients: the RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulation Therapy), J Am Coll Cardiol. 4 févr, vol.63, issue.4, pp.321-329, 2014.

W. Mueck, J. Stampfuss, D. Kubitza, and M. Becka, Clinical Pharmacokinetic and Pharmacodynamic Profile of Rivaroxaban, Clinical Pharmacokinetics, vol.53, issue.1, pp.1-16, 2013.

J. Douxfils, W. Ageno, C. Samama, S. Lessire, H. Ten-cate et al., Laboratory testing in patients treated with direct oral anticoagulants: a practical guide for clinicians, Journal of Thrombosis and Haemostasis, vol.16, issue.2, pp.209-219, 2017.

W. E. Dager, R. C. Gosselin, S. Kitchen, and D. Dwyre, Dabigatran Effects on the International Normalized Ratio, Activated Partial Thromboplastin Time, Thrombin Time, and Fibrinogen: A Multicenter, In Vitro Study, Annals of Pharmacotherapy, vol.46, issue.12, pp.1627-1636, 2012.

M. Schmohl, D. Gansser, V. Moschetti, and J. Stangier, Measurement of dabigatran plasma concentrations by calibrated thrombin clotting time in comparison to LC-MS/MS in human volunteers on dialysis, Thrombosis Research, vol.135, issue.3, pp.532-536, 2015.

J. P. Antovic, M. Skeppholm, J. Eintrei, E. E. Boija, L. Söderblom et al., Evaluation of coagulation assays versus LC-MS/MS for determinations of dabigatran concentrations in plasma, European Journal of Clinical Pharmacology, vol.69, issue.11, pp.1875-1881, 2013.

S. D. Jones, N. S. Eaddy, and G. T. Chan, Dabigatran: laboratory monitoring, Pathology, vol.44, issue.6, pp.578-580, 2012.

J. Douxfils, F. Mullier, S. Robert, C. Chatelain, B. Chatelain et al., Impact of dabigatran on a large panel of routine or specific coagulation assays. Laboratory recommendations for monitoring of dabigatran etexilate, Thromb Haemost. mai, vol.107, issue.5, pp.985-97, 2012.

J. Van-ryn, J. Stangier, S. Haertter, K. Liesenfeld, W. Wienen et al., Dabigatran etexilate--a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity, Thromb Haemost. juin, vol.103, issue.6, pp.1116-1143, 2010.

T. A. Helin, A. Pakkanen, R. Lassila, and L. Joutsi-korhonen, Laboratory Assessment of Novel Oral Anticoagulants: Method Suitability and Variability between Coagulation Laboratories, Clinical Chemistry, vol.59, issue.5, pp.807-814, 2013.

E. M. Hawes, A. M. Deal, D. Funk-adcock, R. Gosselin, C. Jeanneret et al., Performance of coagulation tests in patients on therapeutic doses of dabigatran: a cross-sectional pharmacodynamic study based on peak and trough plasma levels, Journal of Thrombosis and Haemostasis, vol.11, issue.8, pp.1493-1502, 2013.

J. Douxfils, B. Chatelain, P. Hjemdahl, B. Devalet, A. Sennesael et al., Does the Russell Viper Venom time test provide a rapid estimation of the intensity of oral anticoagulation? A cohort study, Thrombosis Research, vol.135, issue.5, pp.852-860, 2015.

L. Seyve, C. Richarme, B. Polack, and R. Marlu, Impact of four direct oral anticoagulants on rotational thromboelastometry (ROTEM), International Journal of Laboratory Hematology, vol.40, issue.1, pp.84-93, 2017.
URL : https://hal.archives-ouvertes.fr/hal-01958965

J. D. Dias, K. Norem, D. D. Doorneweerd, R. L. Thurer, M. A. Popovsky et al., Use of Thromboelastography (TEG) for Detection of New Oral Anticoagulants, Archives of Pathology & Laboratory Medicine, vol.139, issue.5, pp.665-673, 2015.

S. Poli, F. Härtig, C. Spencer, M. Ebner, I. Birschmann et al., Diagnostic Accuracy of a Novel Chromogenic Direct Thrombin Inhibitor Assay: Clinical Experiences for Dabigatran Monitoring, Thrombosis and Haemostasis, vol.117, issue.12, pp.2369-2375, 2017.

M. Ebner, I. Birschmann, A. Peter, F. Härtig, C. Spencer et al., Limitations of Specific Coagulation Tests for Direct Oral Anticoagulants: A Critical Analysis, Journal of the American Heart Association, vol.7, issue.19, p.9807, 2018.

F. Mullier, J. Douxfils, A. Tamigniau, J. Dogné, M. Horellou et al., Non-VKA oral anticoagulants: an update for the clinical biologists, Annales de biologie clinique, vol.73, issue.3, pp.333-344, 2015.

C. H. Berthelot, Le Second Congrès International des Pétroles, Revue de Métallurgie, vol.35, issue.2, pp.73-85, 1938.

M. M. Samama, G. Contant, T. E. Spiro, E. Perzborn, L. L. Flem et al., Evaluation of the Prothrombin Time for Measuring Rivaroxaban Plasma Concentrations Using Calibrators and Controls, Clinical and Applied Thrombosis/Hemostasis, vol.18, issue.2, pp.150-158, 2012.

A. Tripodi, V. Chantarangkul, C. Guinet, and M. M. Samama, The International Normalized Ratio calibrated for rivaroxaban has the potential to normalize prothrombin time results for rivaroxaban-treated patients: results of an in vitro study, Journal of Thrombosis and Haemostasis, vol.9, issue.1, pp.226-228, 2011.

S. J. Francart, E. M. Hawes, A. M. Deal, D. M. Adcock, R. Gosselin et al., Performance of coagulation tests in patients on therapeutic doses of rivaroxaban. A crosssectional pharmacodynamic study based on peak and trough plasma levels, Thromb Haemost. juin, vol.111, issue.6, pp.1133-1173, 2014.

A. Tripodi, L. Padovan, C. Veena, E. Scalambrino, S. Testa et al., How the Direct Oral Anticoagulant Apixaban Affects Thrombin Generation Parameters, Thrombosis Research, vol.135, issue.6, pp.1186-1190, 2015.

B. J. Dale, J. S. Ginsberg, M. Johnston, J. Hirsh, J. I. Weitz et al., Comparison of the effects of apixaban and rivaroxaban on prothrombin and activated partial thromboplastin times using various reagents, Journal of Thrombosis and Haemostasis, vol.12, issue.11, pp.1810-1815, 2014.

A. Dincq, S. Lessire, B. Chatelain, M. Gourdin, J. Dogné et al., Impact of the Direct Oral Anticoagulants on Activated Clotting Time, Journal of Cardiothoracic and Vascular Anesthesia, vol.31, issue.1, pp.e24-e27, 2017.

J. Graff, N. Von-hentig, F. Misselwitz, D. Kubitza, M. Becka et al., Effects of the Oral, Direct Factor Xa Inhibitor Rivaroxaban on Platelet-Induced Thrombin Generation and Prothrombinase Activity1, The Journal of Clinical Pharmacology, vol.47, issue.11, pp.1398-1407, 2007.

J. Douxfils, A. Tamigniau, B. Chatelain, C. Chatelain, P. Wallemacq et al., Comparison of calibrated chromogenic anti-Xa assay and PT tests with LC-MS/MS for the therapeutic monitoring of patients treated with rivaroxaban, Thromb Haemost, vol.110, issue.4, pp.723-754, 2013.

Y. C. Barrett, Z. Wang, C. Frost, and A. Shenker, Clinical laboratory measurement of direct factor Xa inhibitors: anti-Xa assay is preferable to prothrombin time assay, Thromb Haemost. déc, vol.104, issue.6, pp.1263-71, 2010.

R. C. Becker, H. Yang, Y. Barrett, P. Mohan, J. Wang et al., Chromogenic laboratory assays to measure the factor Xa-inhibiting properties of apixaban?an oral, direct and selective factor Xa inhibitor, Journal of Thrombosis and Thrombolysis, vol.32, issue.2, pp.183-187, 2011.

R. C. Gosselin, S. J. Francart, E. M. Hawes, S. Moll, W. E. Dager et al., Heparin-Calibrated Chromogenic Anti-Xa Activity Measurements in Patients Receiving Rivaroxaban, Annals of Pharmacotherapy, vol.49, issue.7, pp.777-783, 2015.

D. A. Bookstaver, K. Sparks, B. S. Pybus, D. K. Davis, S. R. Marcsisin et al., Comparison of Anti-Xa Activity in Patients Receiving Apixaban or Rivaroxaban, Annals of Pharmacotherapy, vol.52, issue.3, pp.251-256, 2017.

S. G. Yates, S. Smith, W. Tharpe, Y. Shen, and R. Sarode, Can an anti-Xa assay for low-molecular-weight heparin be used to assess the presence of rivaroxaban?, Transfusion and Apheresis Science, vol.55, issue.2, pp.212-215, 2016.

S. Margeti?, I. ?elap, V. Ba?i?-kes, A. Lovren?i?-huzjan, I. Kobasi? et al., Chromogenic anti-FXa assay calibrated with low molecular weight heparin in patients treated with rivaroxaban and apixaban, Biochemia medica, vol.30, issue.1, pp.74-82, 2020.

J. Beyer, T. Trujillo, S. Fisher, A. Ko, S. E. Lind et al., Evaluation of a Heparin-Calibrated Antifactor Xa Assay for Measuring the Anticoagulant Effect of Oral Direct Xa Inhibitors, Clinical and Applied Thrombosis/Hemostasis, vol.22, issue.5, pp.423-428, 2016.

R. Gosselin, R. P. Grant, and D. M. Adcock, Comparison of the effect of the anti-Xa direct oral anticoagulants apixaban, edoxaban, and rivaroxaban on coagulation assays, International Journal of Laboratory Hematology, vol.38, issue.5, pp.505-513, 2016.

L. Sabor, M. Raphaël, J. Dogné, F. Mullier, and J. Douxfils, Heparin-calibrated chromogenic anti-Xa assays are not suitable to assess the presence of significant direct factor Xa inhibitors levels, Thrombosis Research, vol.156, pp.36-38, 2017.

P. Y. Kim, C. H. Yeh, B. J. Dale, B. A. Leslie, A. R. Stafford et al., Mechanistic Basis for the Differential Effects of Rivaroxaban and Apixaban on Global Tests of Coagulation, TH Open, vol.02, issue.02, pp.e190-e201, 2018.

P. Kim, C. Yeh, B. Dale, B. Leslie, A. Stafford et al., Mechanistic Basis for the Differential Effects of Rivaroxaban and Apixaban on Global Tests of Coagulation, TH Open, vol.02, issue.02, pp.e190-e201, 2018.

P. Hallouët, Accident ischémique transitoire (AIT) ? Accident vasculaire cérébral (AVC), Mémo-guide infirmier, pp.324-329, 2010.

D. Sur, Collège des Enseignants de Neurologie -5ème Edition (Edition Elsevier Masson), disponible via l'ENT de l

D. Sur, Nouveau Stade de Bordeaux, Bordeaux, FR, Herzog & de Meuron, 2017.

. Dgos,

S. Ministère-des, L. De, and . Santé, , 2020.

, Mortalité par accident vasculaire cérébral (AVC), 2017 et variation 2000?17 (ou année la plus proche), 2019.

, COVID-19, traçage épidémiologique et éthique médicale, Bulletin de l'Académie Nationale de Médecine, vol.204, issue.7, pp.703-704, 2020.

D. Sur,

F. H. Netter, About the Illustrator, Netter's Atlas of Human Embryology, Updated Edition, pp.ix-x, 2012.

D. Sur, LAS VEGAS SANDS CORP., a Nevada corporation, Plaintiff, v. UKNOWN REGISTRANTS OF www.wn0000.com, www.wn1111.com, www.wn2222.com, www.wn3333.com, www.wn4444.com, www.wn5555.com, www.wn6666.com, www.wn7777.com, www.wn8888.com, www.wn9999.com, www.112211.com, www.4456888.com, www.4489888.com, www.001148.com, and www.2289888.com, Defendants., Gaming Law Review and Economics, vol.20, issue.10, pp.859-868, 2016.

L. Huguette, Rapport d'évaluation technologique HAS, Organisation de la prise en charge précoce de l'accident vasculaire cérébral ischémique aigu par thrombectomie mécanique, Juillet, p.133, 2018.

, FEVR

D. Sur, https://kujss.iraqjournals.com/pdf_166170_8dd024058ce4abb6c364bec514cecef8.html, Kirkuk University Journal-Scientific Studies, vol.15, issue.2, pp.1-16, 2020.

B. Campbell, P. J. Mitchell, L. Churilov, N. Yassi, T. J. Kleinig et al., Tenecteplase versus Alteplase before Thrombectomy for Ischemic Stroke, N Engl J Med, vol.26, issue.17, pp.1573-82, 2018.

B. Kheiri, M. Osman, A. Abdalla, T. Haykal, S. Ahmed et al., Tenecteplase versus alteplase for management of acute ischemic stroke: a pairwise and network meta-analysis of randomized clinical trials, Journal of Thrombosis and Thrombolysis, vol.46, issue.4, pp.440-450, 2018.

D. Sur,

R. G. Nogueira, A. P. Jadhav, D. C. Haussen, A. Bonafe, R. F. Budzik et al., Thrombectomy 6 to 24 Hours after Stroke with a Mismatch between Deficit and Infarct, N Engl J Med, vol.378, issue.1, pp.11-21, 2018.
URL : https://hal.archives-ouvertes.fr/hal-02387070

G. W. Albers, M. P. Marks, S. Kemp, S. Christensen, J. P. Tsai et al., Thrombectomy for Stroke at 6 to 16 Hours with Selection by Perfusion Imaging, New England Journal of Medicine, vol.378, issue.8, pp.708-718, 2018.

W. J. Powers, A. A. Rabinstein, T. Ackerson, O. M. Adeoye, N. C. Bambakidis et al., Correction to: Guidelines for the Early Management of Patients With Acute Ischemic Stroke: 2019 Update to the 2018 Guidelines for the Early Management of Acute Ischemic Stroke: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association, Stroke, vol.50, issue.12, pp.440-441, 2019.

N. Ahmed, T. Steiner, V. Caso, and N. Wahlgren, Recommendations from the ESO-Karolinska Stroke Update Conference, Stockholm 13?15 November 2016, European Stroke Journal, vol.2, issue.2, pp.95-102, 2017.

J. C. Purrucker, K. Haas, M. Wolf, T. Rizos, S. Khan et al., Haemorrhagic Transformation after Ischaemic Stroke in Patients Taking Non-vitamin K Antagonist Oral Anticoagulants, Journal of Stroke, vol.19, issue.1, pp.67-76, 2017.

Y. Sakamoto, S. Okubo, C. Nito, S. Suda, N. Matsumoto et al., The relationship between stroke severity and prior direct oral anticoagulant therapy in patients with acute ischaemic stroke and non-valvular atrial fibrillation, European Journal of Neurology, vol.24, issue.11, pp.1399-1406, 2017.

T. R. Meinel, S. Frey, M. Arnold, S. Kendroud, U. Fischer et al., Clinical presentation, diagnostic findings and management of cerebral ischemic events in patients on treatment with non-vitamin K antagonist oral anticoagulants ? A systematic review, PLOS ONE, vol.14, issue.3, p.e0213379, 2019.

M. Cappellari and P. Bovi, Intravenous thrombolysis for stroke in patients taking non-VKA oral anticoagulants: an update, Thromb Haemost. août, vol.114, issue.2, pp.440-444, 2015.

M. Liu, Y. Zheng, and G. Li, Safety of Recanalization Therapy in Patients with Acute Ischemic Stroke Under Anticoagulation: A Systematic Review and Meta-Analysis, Journal of Stroke and Cerebrovascular Diseases, vol.27, issue.9, pp.2296-2305, 2018.

L. Drouet, C. Bal-dit-sollier, T. Steiner, and J. Purrucker, Measuring non-vitamin K antagonist oral anticoagulant levels: When is it appropriate and which methods should be used?, International Journal of Stroke, vol.11, issue.7, pp.748-758, 2016.

E. Touzé, Y. Gruel, I. Gouin-thibault, P. Sie, L. Derex et al., , p.22

J. Kepplinger, A. Prakapenia, K. Barlinn, G. Siegert, S. Gehrisch et al., Standardized use of novel oral anticoagulants plasma level thresholds in a new thrombolysis decision making protocol, Journal of Thrombosis and Thrombolysis, vol.41, issue.2, pp.293-300, 2015.

H. Bertillot, Mesurer la qualité pour rationaliser l?hôpital. La genèse des indicateurs de qualité et de sécurité des soins en France, Informations sociales, vol.n° 198, issue.3, p.38, 2018.

T. S. Li and J. Spaulding, A PDF upload option for proposal creation, Données, 2016.

C. Blanc-labarre, B. Delpont, M. Hervieu-bègue, G. Osseby, F. Ricolfi et al., Prise en charge aiguë des infarctus cérébraux en 2017, La Revue de Médecine Interne, vol.39, issue.6, pp.408-413, 2018.

, Littérature commentée juin 2018, La Revue de Médecine Interne, vol.39, issue.6, pp.449-451, 2018.

E. Boissier, L. Calmette, B. Delahousse, C. Flaujac, M. Françoise et al., Sécurité et productivité en hémostase, Revue Francophone des Laboratoires, vol.2013, issue.450, p.18, 2013.

R. Mcgrail, J. Revsholm, P. H. Nissen, E. L. Grove, and A. Hvas, Stability of direct oral anticoagulants in whole blood and plasma from patients in steady state treatment, Thrombosis Research, vol.148, pp.107-110, 2016.

D. Sur, SERMENT DE GALIEN Je jure, en présence des maîtres de la Faculté et de mes condisciples : ? D'honorer ceux qui m'ont instruite dans les préceptes de mon art et de leur témoigner ma reconnaissance en restant fidèle à leur enseignement

?. , intérêt de la santé publique, ma profession avec conscience et de respecter non seulement la législation en vigueur, mais aussi les règles de l'honneur

, Le principe de dignité humaine et le personnalisme éthique, Travaux du IXe Congrès International de Philosophie, pp.104-107, 1937.

S. Rochat, Utiliser l?analyse fonctionnelle pour favoriser l?insertion professionnelle des jeunes en rupture d?apprentissage, L?Orientation scolaire et professionnelle, issue.45/3, 2016.

M. Demélas-bohy, «Je suis oiseau ; voyez mes ailes...», «Je suis souris : vive les rats !», Caravelle, vol.62, issue.1, pp.179-191, 1994.

, Si je constate une violation de mes droits de propriété intellectuelle, que dois-je ou que puis-je faire?, 2004.